Abstract
Patients with first venous thromboembolism (VTE) and high factor VIII (FVIII) are at increased risk of recurrence. It is unknown whether these patients benefit from prolonged secondary thrombophrophylaxis. In a prospective trial patients with first spontaneous VTE and FVIII levels >230 IU/dl were randomized to discontinue vitamin K Antagonist (VKA) after 6 months or to continue VKA for additional 24 months. Patients were excluded if they had a natural inhibitor deficiency, lupus anticoagulant, cancer, were pregnant, required long-term antithrombotic therapy or had acute-phase reaction. Primary study endpoints were symptomatic recurrent VTE or major bleeding within 2 years. Follow-up was continued beyond 2 years. Of 3,219 screened patients 34 met the inclusion criteria. Mean observation time was 37 months. Two of 17 patients allocated to discontinue VKA and two of 17 patients randomized to prolonged anticoagulation had recurrent VTE within 2 years. In the prolonged treatment group, one patient had recurrence during VKA therapy and one patient 4 weeks after voluntary discontinuation of VKA. One major nonfatal bleeding (severe epistaxis) after 10 months of VKA occurred in the prolonged treatment group. Five patients allocated to prolonged anticoagulation had recurrent VTE after discontinuation of VKA. The probability of recurrence at 2 years after discontinuation of VKA was 30% (95% CI 13–46%). Patients with high FVIII are at increased risk of recurrence. Our findings in a small number of patients indicate that prolonged anticoagulation seems to be effective but that the benefit is not maintained after discontinuation of anticoagulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–155 doi:10.1016/S0140-6736(95)90166-3
O’Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M (1997) High prevalence of high factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 77:825–828
Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor levels and the risk of recurrent venous thromboembolism. N Engl J Med 343:457–462 doi:10.1056/NEJM200008173430702
Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P (2004) High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 124:504–510 doi:10.1046/j.1365-2141.2003.04795.x
Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293:2352–2361 doi:10.1001/jama.293.19.2352
Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S (2004) Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and hrombolytic Therapy. Chest 126:287S–310S
Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Kjell-Ake J, Hjorth M, Linder O, Boberg J, Duration of Anticoagulation Trial Study Group (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332:1661–1665 doi:10.1056/NEJM199506223322501
Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 336:393–398 doi:10.1056/NEJM199702063360601
Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428 doi:10.1016/S0140-6736(96)01109-9
van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76:12–16
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481 doi:10.2307/2281868
Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191–1194 doi:10.1016/S0140-6736(00)04337-3
Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Warfarin Optimal Duration Italian Trial Investigators (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345:165–169 doi:10.1056/NEJM200107193450302
Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S (2004) The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350:2558–2563 doi:10.1056/NEJMoa032959
Eichinger S, Weltermann A, Minar E, Stain M, Schönauer V, Schneider B, Kyrle PA (2004) Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 164:92–96 doi:10.1001/archinte.164.1.92
Murin S, Romano PS, White RH (2002) Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 88:407–414
Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P (2007) The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 147:766–774
Acknowledgements
E. Minar (Univ. Klinik für Innere Medizin II, Abt. für Angiologie, Medizinische Universität Wien, Wien), K. Janata-Schwatzcek (Univ. Klinik für Notfallmedizin, Medizinische Universität Wien, Wien), K. Böhler (Univ. Klinik für Dermatologie, Medizinische Universität Wien, Wien), C. Bialonczyk (Wilhelminenspital, Wien), M. Hirschl (Hanuschkrankenhaus, Wien), U. Köller (Krankenhaus Lainz, Wien), W. Halbmayer (Krankenhaus Lainz, Wien), A. Stümpflen (Krankenhaus Lainz, Wien), W. Weismüller (Kaiser-Franz-Josef-Spital, Wien), K.H. Tragl (Donauspital, Wien), A. Somloi (Donauspital, Wien), W. Hinterberger (Donauspital, Wien), M. Fangl (Donauspital, Wien), M. Atteneder (Gesundheitszentrum Wien Mitte, Wien), G. Aspöck (Krankenhaus der Barmherzigen Schwestern, Wels), M. Heistinger (Landeskrankenhaus Klagenfurt, Klagenfurt), B. Schneeweiss (Landeskrankenhaus Kirchdorf, Kirchdorf); all Austria.
Funding
This work was supported by the Kamillo-Eisner-Stiftung.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Eischer, L., Gartner, V., Schulman, S. et al. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol 88, 485–490 (2009). https://doi.org/10.1007/s00277-008-0626-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0626-1